BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 37760536)

  • 1. Negative Survival Impact of Occult Lymph Node Involvement in Small HER2-Positive Early Breast Cancer Treated by Up-Front Surgery.
    Houvenaeghel G; Cohen M; Martino M; Reyal F; Classe JM; Chauvet MP; Colombo PE; Heinemann M; Jouve E; Gimbergues P; Azuar AS; Coutant C; Gonçalves A; de Nonneville A
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of prognostic impact of sentinel node micro-metastases in endocrine receptor-positive early breast cancer: results from a large multicenter cohort
    Houvenaeghel G; de Nonneville A; Cohen M; Chopin N; Coutant C; Reyal F; Mazouni C; Gimbergues P; Azuar AS; Chauvet MP; Classe JM; Daraï E; Martinez A; Rouzier R; de Lara CT; Lambaudie E; Barrou J; Goncalves A
    ESMO Open; 2021 Jun; 6(3):100151. PubMed ID: 33984674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors of isolated tumor cells and micrometastases in axillary lymph nodes in breast cancer.
    Madsen EV; Elias SG; van Dalen T; van Oort PM; van Gorp J; Gobardhan PD; Bongers V
    Breast; 2013 Oct; 22(5):748-52. PubMed ID: 23313060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daily Practice Management of pT1a-b pN0 Breast Carcinoma: A Prospective French ODISSEE Cohort Study.
    Dalenc F; Penault-Llorca F; Cohen M; Houvenaeghel G; Piat JM; Liegeois P; Puyuelo L; Suchaud JP; Zouai M; Lacroix-Triki M; Radosevic-Robin N; Benkanoun C; Attar-Rabia H; Chauvet MP; Gligorov J; Belkacemi Y
    Clin Breast Cancer; 2017 Apr; 17(2):107-116. PubMed ID: 27856201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controversies in locoregional management of breast cancer with low volume pN0(i+) and pN1mi nodal disease.
    Dosani M; Truong PT
    Expert Rev Anticancer Ther; 2019 Sep; 19(9):803-810. PubMed ID: 31498712
    [No Abstract]   [Full Text] [Related]  

  • 6. pN0(i+) and pN1mi Breast Cancer: Treatment and Outcomes in Comparison With pN0 and pN1a in the Modern Era.
    Dosani M; Hamilton SN; Gondara L; Speers C; Diocee RM; Nichol A; Lohrisch C; Truong P
    Int J Radiat Oncol Biol Phys; 2022 Jul; 113(4):805-815. PubMed ID: 35385784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Lobular invasive breast cancer prognostic factors: About 940 patients].
    Jauffret C; Houvenaeghel G; Classe JM; Garbay JR; Giard S; Charitansky H; Cohen M; Bélichard C; Faure C; Darai É; Hudry D; Azuar P; Villet R; Gimbergues P; Tunon de Lara C; Martino M; Coutant C; Dravet F; Chauvet MP; Chéreau Ewald E; Penault-Llorca F; Goncalves A; Lambaudie É
    Gynecol Obstet Fertil; 2015 Nov; 43(11):712-7. PubMed ID: 26482833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological significance of occult micrometastases in histologically negative axillary lymph nodes in breast cancer patients using the recent American Joint Committee on Cancer breast cancer staging system.
    Kahn HJ; Hanna WM; Chapman JA; Trudeau ME; Lickley HL; Mobbs BG; Murray D; Pritchard KI; Sawka CA; McCready DR; Marks A
    Breast J; 2006; 12(4):294-301. PubMed ID: 16848838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes in Premenopausal Patients with HR+/HER2- Breast Cancer and Lymph Node Micrometastasis Based on the 21-Gene Recurrence Score.
    Bilani N; Patel R; Crowley F; Tiersten A
    Oncologist; 2023 Dec; 28(12):1049-1054. PubMed ID: 37682780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement.
    Colleoni M; Rotmensz N; Peruzzotti G; Maisonneuve P; Mazzarol G; Pruneri G; Luini A; Intra M; Veronesi P; Galimberti V; Torrisi R; Cardillo A; Goldhirsch A; Viale G
    J Clin Oncol; 2005 Mar; 23(7):1379-89. PubMed ID: 15735114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axillary lymph node nanometastases are prognostic factors for disease-free survival and metastatic relapse in breast cancer patients.
    Querzoli P; Pedriali M; Rinaldi R; Lombardi AR; Biganzoli E; Boracchi P; Ferretti S; Frasson C; Zanella C; Ghisellini S; Ambrogi F; Antolini L; Piantelli M; Iacobelli S; Marubini E; Alberti S; Nenci I
    Clin Cancer Res; 2006 Nov; 12(22):6696-701. PubMed ID: 17121888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of nodal metastases in early stage HER2+ breast cancer: Deciding on treatment approach with neoadjuvant chemotherapy vs. upfront surgery.
    Faleh S; Prakash I; Eisenberg E; Basik M; Boileau JF; Tejera D; Panet F; Buhlaiga N; Meterissian S; Wong SM
    Eur J Surg Oncol; 2023 Aug; 49(8):1411-1416. PubMed ID: 37031045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clustering Molecular Subtypes in Breast Cancer, Immunohistochemical Parameters and Risk of Axillary Nodal Involvement.
    Pereira A; Siegrist J; Lizarraga S; Pérez-Medina T
    J Pers Med; 2022 Aug; 12(9):. PubMed ID: 36143189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can axillary node dissection be safely omitted in the elderly? A retrospective study on axillary management of early breast cancer in older women.
    Esposito E; Sollazzo V; Di Micco R; Cervotti M; Luglio G; Benassai G; Mozzillo P; Perrotta S; Desiato V; Amato B; Forestieri P; Limite G
    Int J Surg; 2016 Sep; 33 Suppl 1():S114-8. PubMed ID: 27353842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sentinel and non-sentinel lymph node metastases in patients with microinvasive breast cancer: a nationwide study.
    Holm-Rasmussen EV; Jensen MB; Balslev E; Kroman N; Tvedskov TF
    Breast Cancer Res Treat; 2019 Jun; 175(3):713-719. PubMed ID: 30877405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer.
    Curigliano G; Viale G; Bagnardi V; Fumagalli L; Locatelli M; Rotmensz N; Ghisini R; Colleoni M; Munzone E; Veronesi P; Zurrida S; Nolè F; Goldhirsch A
    J Clin Oncol; 2009 Dec; 27(34):5693-9. PubMed ID: 19884553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of the pathological lymph node status on adjuvant systemic treatment recommendations in clinically node negative breast cancer patients.
    van Roozendaal LM; Schipper RJ; Van de Vijver KK; Haekens CM; Lobbes MB; Tjan-Heijnen VC; de Boer M; Smidt ML
    Breast Cancer Res Treat; 2014 Feb; 143(3):469-76. PubMed ID: 24390150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic significance of intranodal isolated tumor cells and micrometastases in patients with non-small cell carcinoma of the lung.
    Marchevsky AM; Qiao JH; Krajisnik S; Mirocha JM; McKenna RJ
    J Thorac Cardiovasc Surg; 2003 Aug; 126(2):551-7. PubMed ID: 12928657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up.
    Tan LK; Giri D; Hummer AJ; Panageas KS; Brogi E; Norton L; Hudis C; Borgen PI; Cody HS
    J Clin Oncol; 2008 Apr; 26(11):1803-9. PubMed ID: 18332473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact and outcomes of routine microstaging of sentinel lymph nodes in breast cancer: significance of the pN0(i+) and pN1mi categories.
    Pugliese MS; Beatty JD; Tickman RJ; Allison KH; Atwood MK; Szymonifka J; Arthurs ZM; Huynh PP; Dawson JH
    Ann Surg Oncol; 2009 Jan; 16(1):113-20. PubMed ID: 18949520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.